Trastuzumab ± Capecitabine Maintenance After the First-Line Treatment of HER2-Positive Advanced Gastric Cancer: Retrospective Observational Real-Life Data of Turkish Oncology Group.

Autor: Gürbüz M; Faculty of Medicine, Department of Medical Oncology, Ankara University, Ankara, Turkey. mgurbuz@ankara.edu.tr., Akkuş E; Faculty of Medicine, Department of Internal Medicine, Ankara University, Ankara, Turkey., Sakin A; Faculty of Medicine, Department of Medical Oncology, Van Yüzüncü Yıl University, Van, Turkey., Urvay S; Department of Medical Oncology, Kayseri Acıbadem Hospital, Kayseri, Turkey., Demiray AG; Faculty of Medicine, Department of Medical Oncology, Pamukkale University, Denizli, Turkey., Şahin S; Department of Medical Oncology, University of Health Sciences, Van Training and Research Hospital, Van, Turkey., Şakalar T; Department of Medical Oncology, Necip Fazıl City Hospital, Kahramanmaraş, Turkey., Erol C; Faculty of Medicine, Department of Medical Oncology, Yıldırım Beyazıt University, Ankara, Turkey., Şendur MAN; Faculty of Medicine, Department of Medical Oncology, Yıldırım Beyazıt University, Ankara, Turkey., Şahin AB; Faculty of Medicine, Department of Medical Oncology, Uludağ University, Bursa, Turkey., Çubukçu E; Faculty of Medicine, Department of Medical Oncology, Uludağ University, Bursa, Turkey., Güven DC; Faculty of Medicine, Department of Medical Oncology, Hacettepe University, Ankara, Turkey., Kılıçkap S; Faculty of Medicine, Department of Medical Oncology, Hacettepe University, Ankara, Turkey., Ergün Y; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey., Uncu D; Department of Medical Oncology, Ankara City Hospital, Ankara, Turkey., Turhal NS; Anadolu Medical Center, Department of Medical Oncology, Kocaeli, Turkey., Üskent N; Anadolu Medical Center, Department of Medical Oncology, Kocaeli, Turkey., Çınkır HY; Faculty of Medicine, Department of Medical Oncology, Gaziantep University, Gaziantep, Turkey., Demir A; Department of Medical Oncology, Maslak Acıbadem Hospital, Istanbul, Turkey., Acar R; Department of Medical Oncology, University of Health Sciences, Gülhane Training and Research Hospital, Ankara, Turkey., Karadurmuş N; Department of Medical Oncology, University of Health Sciences, Gülhane Training and Research Hospital, Ankara, Turkey., Türker S; Department of Medical Oncology, Diskapi Yildirim Beyazid Education and Research Hospital, Ankara, Turkey., Altınbaş M; Department of Medical Oncology, Diskapi Yildirim Beyazid Education and Research Hospital, Ankara, Turkey., Karaoğlan M; Faculty of Medicine, Department of Internal Medicine, Ankara University, Ankara, Turkey., Şenler FÇ; Faculty of Medicine, Department of Medical Oncology, Ankara University, Ankara, Turkey.
Jazyk: angličtina
Zdroj: Journal of gastrointestinal cancer [J Gastrointest Cancer] 2022 Jun; Vol. 53 (2), pp. 282-288. Date of Electronic Publication: 2021 Feb 04.
DOI: 10.1007/s12029-021-00594-1
Abstrakt: Purpose: In the ToGA trial for HER2-positive advanced gastric cancer, cisplatin plus fluoropyrimidine was given for 6 cycles; trastuzumab was given until disease progression. However, there is a lack of real-life data about trastuzumab maintenance after 6 cycle chemotherapy. This study aims to present real-life data of trastuzumab ± capecitabine maintenance after 6 cycles of platinum, fluoropyrimidine, and trastuzumab in non-progressive patients.
Methods: This is a retrospective multicenter study of the Turkish Oncology Group. A total of 35 HER2-positive, inoperable locally advanced, recurrent, or metastatic gastric adenocarcinoma patients being non-progressive at the end of 6 cycle chemotherapy and being given trastuzumab ± capecitabine as maintenance treatment were included from sixteen oncology centers. Baseline characteristics, objective tumor responses, progression free and overall survival data, and toxicities were determined.
Results: About 68% of the patients were given CF, and 32% were given FOLFOX with trastuzumab as the first-line treatment. The best response in 6 cycle chemotherapy was complete 8 (22%), partial 24 (68%), and stable disease 3 (8%). All patients had trastuzumab maintenance (median cycle 13; range 7-51), and 49% of the patients had capecitabine with trastuzumab (median capecitabine cycle 6; range 2-30). The median PFS of the patients was 12.0 months (95% CI 10.3-13.7), and median OS was 17.4 months (95% CI 15.2-19.5). There were 2 patients with grade 1 cardiotoxicity.
Conclusion: Trastuzumab maintenance ± capecitabine after 6 cycles of trastuzumab plus combined chemotherapy treatment revealed efficacy and safety in non-progressive HER2-positive advanced gastric cancer.
(© 2021. Springer Science+Business Media, LLC, part of Springer Nature.)
Databáze: MEDLINE
Externí odkaz: